Law360, New York (December 15, 2011, 6:03 PM ET) -- Shire LLC slapped Mylan Inc. with another patent suit over the attention deficit hyperactivity disorder drug Intuniv in West Virginia federal court Thursday, after Mylan changed its bid for regulatory approval of generic Intuniv to include three more dosage strengths.
The plaintiffs — a group that includes Shire and Supernus Pharmaceuticals Inc. — lodged their complaint in federal court in Clarksburg, the same venue in which Shire targeted Mylan and subsidiary Mylan Pharmaceuticals Inc. with a patent suit over Intuniv in April.
The April suit followed...
Shire Takes Aim At Mylan Again In New Intuniv Patent Suit
To view the full article, take a free trial now.
